Which angiotensin‑receptor blockers and dosing regimens are recommended for a patient with chronic systolic heart failure who cannot tolerate an ACE inhibitor due to cough, angio‑edema, or other adverse effects?

ARBs for Chronic Systolic Heart Failure in ACE Inhibitor-Intolerant Patients

For patients with chronic systolic heart failure who cannot tolerate ACE inhibitors due to cough or angioedema, ARBs are the recommended alternative and should be initiated at low doses and titrated to the target doses proven effective in clinical trials. 1

Recommended ARBs and Target Doses

The following ARBs have demonstrated mortality and morbidity reduction in large randomized controlled trials for heart failure with reduced ejection fraction:

Evidence-Based ARB Regimens

While the 2017 ACC/AHA/HFSA guidelines establish that ARBs reduce morbidity and mortality in ACE inhibitor-intolerant patients, the specific ARBs and doses proven effective in major heart failure trials include: 1

• Candesartan: Start 4-8 mg once daily, target 32 mg once daily
• Valsartan: Start 40 mg twice daily, target 160 mg twice daily
• Losartan: Start 25-50 mg once daily, target 50-150 mg once daily

These agents have been studied in landmark trials demonstrating reduction in cardiovascular death and heart failure hospitalizations. 1, 2

Initiation and Titration Protocol

Start low and go slow, following this systematic approach: 1

• Begin at the lowest recommended starting dose
• Double the dose at 2-week intervals as tolerated
• Aim for target doses shown effective in clinical trials
• Monitor blood pressure, renal function (creatinine), and potassium before initiation, 1-2 weeks after each dose increase, and then every 3-6 months 1

Critical Safety Considerations

When to Use Caution

ARBs should be given with extreme caution in patients with: 1

• Hypotension: Systolic blood pressure <90 mmHg
• Renal insufficiency: Creatinine >2.5 mg/dL (>221 μmol/L)
• Hyperkalemia: Potassium >5.0 mEq/L

Acceptable Laboratory Changes

Creatinine increases up to 50% above baseline or to 3 mg/dL (266 μmol/L), whichever is greater, are acceptable and expected. 1 Potassium levels up to 5.5 mEq/L are generally tolerable. 1

Important Caveat About Angioedema

Although ARBs are alternatives for ACE inhibitor-induced angioedema, some patients have also developed angioedema with ARBs—use with caution and close monitoring. 1 The incidence is lower than with ACE inhibitors but not zero. 1, 3

Key Advantages Over ACE Inhibitors

ARBs offer specific benefits for intolerant patients: 1, 4

• Significantly lower incidence of cough (the most common reason for ACE inhibitor discontinuation)
• Lower risk of angioedema compared to ACE inhibitors (though not eliminated)
• Better overall tolerability with fewer withdrawals due to adverse effects 5

Clinical Effectiveness

ARBs produce hemodynamic, neurohormonal, and clinical effects consistent with renin-angiotensin system blockade and have been proven in randomized controlled trials to reduce morbidity and mortality, especially in ACE inhibitor-intolerant patients. 1 They reduce heart failure hospitalizations and cardiovascular death with efficacy approaching that of ACE inhibitors. 1, 2

When ARBs Are NOT the Answer

If the patient can tolerate an ACE inhibitor or is eligible for sacubitril/valsartan (ARNI), those options are preferred over ARBs alone. 1 The PARADIGM-HF trial demonstrated that sacubitril/valsartan is superior to enalapril in reducing cardiovascular death and heart failure hospitalization in patients with NYHA class II-IV heart failure. 4

For patients already on an ACE inhibitor who develop symptomatic heart failure, replacement with an ARNI is recommended to further reduce morbidity and mortality (Class I, Level B-R recommendation). 1

Common Pitfalls to Avoid

• Do not use subtherapeutic doses—the most common error is failing to titrate to target doses proven effective in trials 1
• Do not discontinue for asymptomatic hypotension—only symptomatic hypotension requires intervention 1
• Do not stop ARBs abruptly—clinical deterioration is likely; seek specialist advice before discontinuation 1
• Do not combine ARB + ACE inhibitor + beta-blocker—this triple combination increases adverse effects without additional benefit 2
• Avoid potassium-sparing diuretics during ARB initiation to prevent dangerous hyperkalemia 1

Problem-Solving Algorithm

If Hypotension Develops:

• Assess for signs of congestion
• If no congestion present, reduce diuretic dose
• Consider reducing or eliminating non-essential vasodilators (nitrates, calcium channel blockers)
• Asymptomatic low blood pressure requires no intervention 1

If Renal Function Worsens:

• Stop nephrotoxic drugs (NSAIDs, potassium supplements)
• If creatinine rises >50% but <100%, reduce diuretic if no congestion
• If creatinine doubles or exceeds 4 mg/dL (354 μmol/L), seek specialist advice 1

If Hyperkalemia Develops:

• Stop potassium supplements and potassium-sparing diuretics
• Reduce diuretic dose if no congestion
• If potassium >6.0 mEq/L, seek specialist advice 1